Profound Medical Corp. (PRN:CA) Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer Transcript
Source: SeekingAlpha
2026-03-13 14:32:18 ET
Profound Medical Corp. (PRN:CA) Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 AM EDT...
Read the full article on Seeking Alpha
For further details see:
Profound Medical Corp. (PRN:CA) Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer Transcript
Profound Medical Corp.
NASDAQ: PROF
PROF Trading
-4.61% G/L:
$5.59 Last:
187,661 Volume:
$5.65 Open:
PROF Latest News
March 13, 2026 10:30:00 am
CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure(TM) to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
March 09, 2026 08:30:00 am
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
March 05, 2026 04:05:00 pm
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
PROF Stock Data
$191,163,115
29,378,933
5.23%
23
N/A
Medical Equipment & Supplies
Healthcare
CA
Mississauga
